Therefore, the role of IRE1 in maintaining plasma cell differentiation and secretory immunoglobulin production in addition to the downregulation of proteins and transcription factors that sustain MM cell survival, suggest that IRE1 inhibitors may not be a proper approach for treating MM. Here, ERN1 is linked to Miyoshi myopathy.